Literature DB >> 2196265

Phase II study of carboplatin and cytosine arabinoside in patients with disseminated malignant melanoma.

N H Mulder1, D T Sleijfer, E G de Vries, H Schraffordt Koops, P H Willemse.   

Abstract

Twenty-one patients with disseminated malignant melanoma were treated with a combination of carboplatin and cytosine arabinoside. Two complete and three partial remissions occurred. No complete cross-resistance was found with a regimen containing 5-(dimethyltriazeno)imidazole-4-carboxamide (DTIC) in two patients. It is suggested that this regimen might be studied further as a second-line treatment for patients who fail on DTIC-containing treatment.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2196265     DOI： 10.1007/bf01612907

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


  10 in total

1.  "Platinum-pyrimidine blues" and related complexes: a new class of potent antitumor agents.

Authors:  J P Davidson; P J Faber; R G Fischer; S Mansy; H J Peresie; B Rosenberg; L VanCamp
Journal:  Cancer Chemother Rep       Date:  1975 Mar-Apr

2.  In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II).

Authors:  D H Kern; C R Morgan; S U Hildebrand-Zanki
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

3.  Phase II study of bleomycin, dacarbazine (DTIC) and vindesine in disseminated malignant melanoma.

Authors:  N H Mulder; D T Sleijfer; E G de Vries; H Schraffordt Koops; M J Samson; P H Willemse
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

Review 4.  Chemotherapy of malignant melanoma.

Authors:  J K Luce
Journal:  Cancer       Date:  1972-12       Impact factor: 6.860

5.  Lack of synergy between cisplatin and cytarabine against ovarian carcinoma in vitro.

Authors:  S B Howell; S Gill
Journal:  Cancer Treat Rep       Date:  1986-03

6.  WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.

Authors:  D Glover; J H Glick; C Weiler; K Fox; D Guerry
Journal:  J Clin Oncol       Date:  1987-04       Impact factor: 44.544

7.  Cytarabine and cisplatin in advanced malignant melanoma.

Authors:  E Bajetta; C Verusio; V Bonfante; G Bonadonna
Journal:  Cancer Treat Rep       Date:  1986-12

8.  Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-beta-D-arabinofuranosylcytosine.

Authors:  J P Bergerat; B Drewinko; P Corry; B Barlogie; D H Ho
Journal:  Cancer Res       Date:  1981-01       Impact factor: 12.701

9.  Phase II trial of carboplatin in advanced malignant melanoma.

Authors:  L M Evans; E S Casper; R Rosenbluth
Journal:  Cancer Treat Rep       Date:  1987-02

10.  Pharmacokinetics of cytosine arabinoside in acute myeloid leukemia.

Authors:  R van Prooijen; E van der Kleijn; C Haanen
Journal:  Clin Pharmacol Ther       Date:  1977-06       Impact factor: 6.875
  10 in total
  3 in total

1.  Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures: a single-center study.

Authors:  S Jelić; N Babović; L Stamatović; M Kreacić; S Matković; I Popov
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

2.  Carboplatinum and cytosine arabinoside in patients with disseminated malignant melanoma. A phase II study.

Authors:  B Jeremic; L Djuric; L Mijatovic
Journal:  Invest New Drugs       Date:  1991-08       Impact factor: 3.850

3.  Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine.

Authors:  D J Propper; J P Braybrooke; N C Levitt; K O'Byrne; K Christodoulos; C Han; D C Talbot; T S Ganesan; A L Harris
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.